# reload+after+2024-01-23 20:46:01.055020
address1§9704 Medical Center Drive
city§Rockville
state§MD
zip§20850
country§United States
phone§301 251 5172
fax§301 251 5321
website§https://www.macrogenics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
fullTimeEmployees§357
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Scott  Koenig M.D., Ph.D.', 'age': 71, 'title': 'President, CEO & Director', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 1059292, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James  Karrels', 'age': 56, 'title': 'Senior VP, CFO & Corporate Secretary', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 626829, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eric Blasius Risser', 'age': 50, 'title': 'Chief Operating Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 651362, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Thomas M. Spitznagel Ph.D.', 'age': 56, 'title': 'Senior Vice President of Technical Operations', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 550974, 'exercisedValue': 204497, 'unexercisedValue': 490417}, {'maxAge': 1, 'name': 'Dr. Ezio  Bonvini', 'age': 69, 'title': 'Senior VP of Research & Chief Scientific Officer', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 612208, 'exercisedValue': 264031, 'unexercisedValue': 199063}, {'maxAge': 1, 'name': 'Mr. Jeffrey Stuart Peters', 'age': 52, 'title': 'Senior VP, General Counsel & Corporate Compliance Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stephen L. Eck M.D., Ph.D.', 'age': 68, 'title': 'Senior VP of Clinical Development & Chief Medical Officer', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 577625, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lynn  Cilinski', 'age': 65, 'title': 'VP, Controller & Treasurer', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§3
compensationRisk§5
shareHolderRightsRisk§7
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§2.029
priceToSalesTrailing12Months§5.003197
currency§USD
dateShortInterest§1702598400
forwardEps§-1.87
pegRatio§-0.09
exchange§NMS
quoteType§EQUITY
shortName§MacroGenics, Inc.
longName§MacroGenics, Inc.
firstTradeDateEpochUtc§1381411800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§322da638-92af-3f5e-9fb0-7915224804a7
gmtOffSetMilliseconds§-18000000
targetHighPrice§17.0
targetLowPrice§10.0
targetMeanPrice§12.78
targetMedianPrice§12.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§9
quickRatio§5.493
grossMargins§-0.78531
ebitdaMargins§-0.79197997
trailingPegRatio§None
